PhilipJMeaseMD

Director, Rheumatology Research, Swedish Medical Center/Providence St. Joseph Health and Clinical Professor University of Washington School of Medicine

Join to view full profile

Dr. Mease is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Mease's full profile

Already have an account?

Office
601 Broadway
# 600
Seattle, WA 98122
Phone+1 206-386-2000

Fax+1 206-386-2083
Is this information wrong?

Education & Training

University of WashingtonFellowship, Rheumatology, 1981 - 1982
University of WashingtonResidency, Internal Medicine, 1977 - 1981
Stanford University School of MedicineClass of 1977

Certifications & Licensure

WA State Medical License 1978 - 2025
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Rheumatology

Awards, Honors, & Recognition

LIfetime Achievement Award National Psoriasis Foundation, 2019
America's Top Doctors Castle Connolly, 2008-2014
Top MD Consumers Checkbook
Super Doctor SuperDoctors.com
Join now to see all

Clinical Trials

Rituxan With or Without Methotrexate in Psoriatic Arthritis Start of enrollment: 2006 Dec 01
Completed
Phase 1
Phase IIB Dose Ranging Study in Subjects With Moderate to Severe Rheumatoid Arthritis Start of enrollment: 2012 Jun 01
Completed
Phase 2
Prospective Evaluation of RINCE to Reduce Fibromyalgia Effects - 301 Start of enrollment: 2014 Jul 01
Terminated
Not Applicable
A Long-Term Efficacy and Safety Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis Start of enrollment: 2015 Sep 14
Completed
Phase 3
A Study of Ixekizumab (LY2439821) in TNF Inhibitor Experienced Participants With Radiographic Axial Spondyloarthritis Start of enrollment: 2016 Apr 12
Completed
Phase 3
A Study of Ixekizumab (LY2439821) in Participants With Nonradiographic Axial Spondyloarthritis Start of enrollment: 2016 Aug 02
Completed
Phase 3
A Long Term Extension Study of Ixekizumab (LY2439821) in Participants With Axial Spondyloarthritis Start of enrollment: 2017 May 09
Completed
Phase 3
Join now to see all

Publications & Presentations

PubMed

Exploring the Effects of Ixekizumab on Pain in Patients with Ankylosing Spondylitis Based on Objective Measures of Inflammation: Post Hoc Analysis from a Large Randomi...
Kurt de Vlam, Walter P Maksymowych, Gaia Gallo, Proton Rahman, Venkatesh Krishnan, Conor J McVeigh, Jeffrey Lisse, Danting Zhu, Rebecca J Bolce, Philip G Conaghan, Phi...> ;Rheumatology and Therapy. 2024 Apr 18
Association of clinical response criteria and disease activity levels with axial spondyloarthritis core domains: results from two phase 3 randomised studies, BE MOBILE...
Victoria Navarro-Compán, Sofia Ramiro, Atul Deodhar, Martin Rudwaleit, Christine de la Loge, Carmen Fleurinck, Vanessa Taieb, Michael F Mørup, Ute Massow, Philip J Mea...> ;RMD Open. 2024 Apr 10
Guselkumab provides durable improvement across psoriatic arthritis disease domains: post hoc analysis of a phase 3, randomised, double-blind, placebo-controlled study.
Laura C Coates, Laure Gossec, Miriam Zimmermann, May Shawi, Emmanouil Rampakakis, Natalie J Shiff, Xie L Xu, Peter Nash, Philip S Helliwell, Alexa P Kollmeier, Philip ...> ;RMD Open. 2024 Mar 26
1 citations
EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update.
Laure Gossec, Andreas Kerschbaumer, Ricardo J O Ferreira, Daniel Aletaha, Xenofon Baraliakos, Heidi Bertheussen, Wolf-Henning Boehncke, Bente Appel Esbensen, Iain B Mc...> ;Annals of the Rheumatic Diseases. 2024 Mar 18
Comparative Effectiveness of Bimekizumab and Guselkumab in Patients with Psoriatic Arthritis at 52 Weeks Assessed Using a Matching-Adjusted Indirect Comparison.
Richard B Warren, Iain B McInnes, Peter Nash, Jean-Marie Grouin, Nikos Lyris, Damon Willems, Vanessa Taieb, Jason Eells, Philip J Mease> ;Rheumatology and Therapy. 2024 Mar 15
Safety of Secukinumab from 1 Million Patient-Years of Exposure: Experience from Post-Marketing Setting and Clinical Trials.
Rui Sun, Mercedes Bustamante, Venkatesh Kumar Gurusamy, Mark Lebwohl, Alice B Gottlieb, Philip J Mease, Atul Deodhar, Weibin Bao, Meryl Mendelson, Brian Porter, Deepa ...> ;Dermatology and Therapy. 2024 Mar 1
Comparative Effectiveness of Bimekizumab and Secukinumab in Patients with Psoriatic Arthritis at 52 Weeks Using a Matching-Adjusted Indirect Comparison.
Philip J Mease, Richard B Warren, Peter Nash, Jean-Marie Grouin, Nikos Lyris, Damon Willems, Vanessa Taieb, Jason Eells, Iain B McInnes> ;Rheumatology and Therapy. 2024 Mar 6
Improvements in Patient-Reported Outcomes Through Six Months of Guselkumab Treatment in Patients With Active Psoriatic Arthritis: Real-World Data From the CorEvitas Ps...
Philip J Mease, Alexis Ogdie, John Tesser, Natalie J Shiff, Ruizhi Sophia Zhao, Soumya D Chakravarty, Michael Kelleman, Rhiannon Dodge, Robert R McLean, Aaron Broadwel...> ;ACR Open Rheumatology. 2024 Feb 28
Work Productivity and General Health Through 2 Years of Guselkumab Treatment in a Phase 3 Randomized Trial of Patients With Active Psoriatic Arthritis.
Jeffrey R Curtis, Iain B McInnes, Proton Rahman, Dafna D Gladman, Steven Peterson, Feifei Yang, Oluwakayode Adejoro, Alexa P Kollmeier, Natalie J Shiff, Chenglong Han,...> ;Rheumatology and Therapy. 2024 Apr 1
Continuous improvement through differential trajectories of individual minimal disease activity criteria with guselkumab in active psoriatic arthritis: post hoc analys...
Laura C Coates, Proton Rahman, Philip J Mease, May Shawi, Emmanouil Rampakakis, Alexa P Kollmeier, Xie L Xu, Soumya D Chakravarty, Iain B McInnes, Lai-Shan Tam> ;BMC Rheumatology. 2024 Feb 4
Evaluating the efficacy of biologics with and without methotrexate in the treatment of psoriatic arthritis: a network meta-analysis.
Philip J Mease, Soumya Reddy, Sarah Ross, Jeffrey R Lisse, Paulo Reis, Kirstin Griffing, Christophe Sapin, Aisha Vadhariya, Daniel E Furst> ;RMD Open. 2024 Jan 31
Effectiveness of Tofacitinib in Patients Initiating Therapy for Psoriatic Arthritis: Results from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry.
Philip J Mease, Pamela Young, Lara Fallon, Rajiv Mundayat, Oluwaseyi Dina, Taylor Blachley, Nicole Middaugh, Alexis Ogdie> ;Rheumatology and Therapy. 2024 Apr 1
Modulation of Interleukin-23 Signaling With Guselkumab in Biologic-Naive Patients Versus Tumor Necrosis Factor Inhibitor-Inadequate Responders With Active Psoriatic Ar...
Siebert, S., Coates, L., Schett, G., Raychaudhuri, S., Chen, W., Gao, S., Seridi, L., Chakravarty, S., Shawi, M., Lavie, F., Sharaf, M., Zimmermann, M., Kollmeier, A.,...> ;Arthritis & Rheumatology. 2024 Jan 22
Difficult-to-treat psoriatic arthritis (D2T PsA): a scoping literature review informing a GRAPPA research project.
Shikha Singla, Andre Ribeiro, Murat Torgutalp, Philip J Mease, Fabian Proft> ;RMD Open. 2024 Jan 8
A Care Coordination Model to Prevent Cardiovascular Events in Patients with Psoriatic Disease: A Multicenter Pilot Study.
Song, W., Garshick, M., Barbieri, J., Shin, D., Báez, S., Papadopoulos, M., Neopaney, A., Fitzsimmons, R., Kalb, R., Mease, P., Craig, E., Koplin, J., Takeshita, J., C...> ;The Journal of Investigative Dermatology. 2024 Jan 4
Unmet need in rheumatology: reports from the Advances in Targeted Therapies meeting, 2023.
Winthrop, K., Mease, P., Kerschbaumer, A., Voll, R., Breedveld, F., Smolen, J., Gottenberg, J., Baraliakos, X., Kiener, H., Aletaha, D., Isaacs, J., Buch, M., Crow, M....> ;Annals of the Rheumatic Diseases. 2024 Mar 12
Exploring the complexities of pain phenotypes: OMERACT 2023 chronic pain working group workshop.
Pickles, T., Cowern, M., Christensen, R., Nielsen, S., Jones, C., Maxwell, L., Shea, B., Touma, Z., Toupin-April, K., Choy, E., Simon, L., Strand, V., Mease, P.> ;Seminars in Arthritis and Rheumatism. 2024 Feb 1
1 citations
Sex-related differences in patient characteristics, and efficacy and safety of advanced therapies in randomised clinical trials in psoriatic arthritis: a systematic li...
Lihi Eder, Sivakami Mylvaganam, Jordi Pardo Pardo, Jennifer Petkovic, Vibeke Strand, Philip Mease, Keith Colaco> ;The Lancet. Rheumatology. 2023 Dec 1
2 citations
Improving the nosology of Long COVID: it is not so simple.
Leonard H Calabrese, Philip J Mease> ;Annals of the Rheumatic Diseases. 2024 Jan 2
1 citations
Efficacy of Guselkumab on Axial-Related Symptoms Through up to 2 Years in Adults with Active Psoriatic Arthritis in the Phase 3, Randomized, Placebo-Controlled DISCOVE...
Philip J Mease, Dafna D Gladman, Denis Poddubnyy, Soumya D Chakravarty, May Shawi, Alexa P Kollmeier, Xie L Xu, Stephen Xu, Atul Deodhar, Xenofon Baraliakos> ;Rheumatology and Therapy. 2023 Dec 1
Efficacy of tofacitinib on enthesitis in patients with active psoriatic arthritis: analysis of pooled data from two phase 3 studies.
Philip J Mease, Ana-Maria Orbai, Oliver FitzGerald, Mohamed Bedaiwi, Dona L Fleishaker, Rajiv Mundayat, Pamela Young, Philip S Helliwell> ;Arthritis Research & Therapy. 2023 Aug 22
2 citations
Six-Month Persistence and Multi-domain Effectiveness of Guselkumab in Adults with Psoriatic Arthritis: Real-World Data from the CorEvitas Psoriatic Arthritis/Spondyloa...
Philip J Mease, Alexis Ogdie, John Tesser, Natalie J Shiff, Iris Lin, Soumya D Chakravarty, Michael Kelleman, Rhiannon Dodge, Robert R McLean, Aaron Broadwell, Arthur ...> ;Rheumatology and Therapy. 2023 Dec 1
Proceedings of the Collaborative Research Network Meeting at the GRAPPA 2022 Annual Meeting.
Beverly Cheok Kuan Ng, Deepak Jadon, Frank Behrens, Maarten de Wit, Oliver FitzGerald, Dafna D Gladman, Philip J Mease, Denis O'Sullivan, Stephen R Pennington, Georg S...> ;The Journal of Rheumatology. 2023 Nov 1
Proceedings of the GRAPPA 2022 Executive Retreat.
Beverly Cheok Kuan Ng, Deepak Jadon, Adewale Adebajo, Gizem Ayan, Kristina Callis Duffin, Vinod Chandran, Laura C Coates, Maria Antonietta D'Agostino, Kurt de Vlam, At...> ;The Journal of Rheumatology. 2023 Nov 1
Project Highlights From the GRAPPA 2022 Annual Meeting: Education Initiatives and Axial Involvement in Psoriatic Arthritis.
Murat Torgutalp, Dafna D Gladman, Oliver FitzGerald, Philip J Mease, Denis Poddubnyy> ;The Journal of Rheumatology. 2023 Nov 1
Join now to see all

Journal Articles

Safety of Ixekizumab in Patients with Psoriatic Arthritis: Results from a Pooled Analysis of Three Clinical Trials
Alice Gottlieb, Philip Mease, Arthritis Care & Research
Dual Inhibition of Tumour Necrosis Factor and Interleukin-17A with ABT-122: Open-Label Long-Term Extension Studies in Rheumatoid Arthritis or Psoriatic Arthritis
Philip Mease, MD, Rheumatology
Pain Mechanisms and Ultrasonic Inflammatory Activity as Prognostic Factors in Patients with Psoriatic Arthritis: A Prospective Cohort Study
Philip Mease, MD, Arthritis Care & Research
Secukinumab Provides Rapid and Sustained Pain Relief in Psoriatic Arthritis over 2 Years: Results from the FUTURE 2 Study
Philip J Mease, Vibeke Strand, BioMed Central
Phase 2 Study of ABT‐122, a TNF‐ and IL‐17A–Targeted Dual Variable Domain Immunoglobulin, in Psoriatic Arthritis with Inadequate Methotrexate Response
Philip Mease, MD, Arthritis & Rheumatology
Join now to see all

Lectures

24-Week Results From the RAPID-PsA Study
Annual European Congress of Rheumatology 2012, Berlin, Germany
24-Week Results From the RAPID-PsA Study
European League Against Rheumatism, Annual European Congress of Rheumatology 2012, Berlin, Germany

Authored Content

Efficacy and Safety of Deucravacitinib (BMS-986165), an Oral, Selective Tyrosine Kinase 2 Inhibitor, in Patients with Active Psoriatic Arthritis: Results from a Phase 2, Randomized, Double-Blind, Placebo-Controlled TrialOctober 2020

Press Mentions

Five Recent Advancements in Arthritis Research over the Past YearMay 22nd, 2023
Brepocitinib Shows Promising Results in Patients with Psoriatic ArthritisMay 22nd, 2023
Brepocitinib Shows Promise for Patients with Psoriatic ArthritisMay 18th, 2023
Join now to see all